Jubilant Therapeutics Brings in Industry Veteran Daniel J. O’Connor as CEO

Yardley, PA, December 5, 2025 (PR Newswire) -- Jubilant Therapeutics announced the appointment of Daniel J. O’Connor as President and Chief Executive Officer, effective December 1, 2025, as the company advances its clinical-stage oncology and autoimmune pipeline. O’Connor brings more than three decades of leadership experience in biotechnology, most recently guiding Ambrx Biopharma through a period of significant value creation that culminated in its acquisition. His prior roles include senior leadership positions at ImClone Systems and Advaxis, where he led late-stage clinical development, capital formation, and strategic partnerships with major pharmaceutical companies.

Read full article here.